Evidence map›Paper›PMID 42599580›Full record

ArticleAdvances in therapy2026

Association Between Efficacy and Pharmacokinetics of DMB-3115 and its Originator Ustekinumab in Patients with Chronic Plaque Psoriasis: An Exposure-Response Analysis.

Hironori Konishi, Takeyuki Shindo, Kazuya Ishiwata, Jun Morita

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hironori KonishiR&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.
Takeyuki ShindoR&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.
Kazuya IshiwataR&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.
Jun MoritaR&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. jun.morita@meiji.com.ORCID http://orcid.org/0000-0002-8242-0812

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDMB-3115 is a biosimilar to ustekinumab (Stelara

methodsThe single-dose DMB-3115-1 and DMB-3115-3 studies enrolled healthy participants. The DMB-3115-2 study enrolled patients with moderate-to-severe chronic plaque psoriasis. It comprised 2 periods (Weeks 0-28 and 28-52), and we used the data through Week 12, during which patients received the assigned treatments at Weeks 0 and 4. Across all studies, participants were randomized to receive subcutaneous DMB-3115 or Stelara. We conducted regression analysis to investigate the relationships between the C

resultsIn the regression analysis, the combined C

conclusionThe difference in C

Indexed as

BiosimilarDMB-3115EfficacyExposure–response analysisPharmacokineticsPopulation-based analysisRandomized controlled trialUstekinumab

Identifiers

PMID42599580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.